Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation - 08/08/16
Summary |
Objectives |
Refractory and recurrent cytomegalovirus (CMV) reactivation were independent risk factors of CMV disease and transplant-related mortality post allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our aims were to identify the recovery of CMV-specific CD8+ T cells with a central memory phenotype (TCM) associated with refractory and recurrent CMV reactivation.
Method |
We analyzed findings in a prospective study comprising (n = 107) post allo-HSCT. CMV-specific CD8+ T cells were determined using HLA class I pentamers together with extended phenotypic analyses.
Result |
The patients with lower level of CMV-specific CD8+ TCM at day 30 post-HSCT had an increased risk of refractory and recurrent CMV (68.5%) comparing with the higher one (13.2%) (p < 0.001) and poorer long term CMV-specific CD8+ T cell reconstitution post-HSCT (p = 0.026). Multivariate analysis revealed that CMV-specific CD8+ TCM at day 30 was an independent prognostic factor for refractory and recurrent reactivation (p = 0.002).
Conclusion |
The CMV-specific CD8+ TCM subset at day 30 post-HSCT is associated with CMV-specific T cell immunity recovery as well as the refractory and recurrent CMV reactivation post-HSCT.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Low level of CMV-specific CD8+ TCM cells at day 30 post-HSCT associated with a high risk of refractory and recurrent CMV. |
• | The level of CMV-specific CD8+ TCM cells at early stage post-HSCT associated with CMV-specific CD8+ T cell reconstitution. |
• | CMV-specific CD8+ TCM cells play a crucial role in controlling and forming immune protection from CMV reactivation post-HSCT. |
Keywords : CMV reactivation, Refractory CMV, CMV-specific CD8+ T cell, Central memory T cell subset, Allogeneic hematopoietic stem cell transplantation
Plan
Vol 73 - N° 3
P. 261-270 - septembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?